Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Vitae Pharmaceuticals (NASDAQ:VTAE.DL)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VTAE.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

airenInDebt (83.43)
Submitted January 28, 2015

Word. Autoimmune disease is the new cancer.They definitely need new treatments for the increasing number of people dealing with fibromyalgia, lupus and other fun diseases.

zzlangerhans (98.83)
Submitted March 21, 2016

I took a 1000 share short position in Vitae at 7.66 the day after they reported positive topline data from their phase IIa trial of oral RORgamma-t inhibitor VTP-43742 for moderate-to-severe psoriasis, despite the fact that I'd never looked at the… More

NASDAQ:VTAE.DL VS S&P 500 (SPY)

NASDAQ:VTAE.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about VTAE.DL.

No one has written a Pitch for VTAE.DL stock yet. Tell us why you think VTAE.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in VTAE.DL.

No players have picked VTAE.DL yet. Tell us why you think VTAE.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VTAE.DL.